“Since our founding, science has remained our central guiding principle. Benchling fits perfectly into this philosophy, providing us a flexible informatics platform that enables our scientists to focus on high-impact research and deliver life-transforming medicines.”
Nicholas PapadopoulosSVP R&D Operations, Regeneron
“With Benchling, we have been able to centralize all of our scientific data in one location. It has significantly facilitated deriving deeper insights from data and helped our company move a step closer to being an insights-driven organization.”
Deven DharmDirector of Software Engineering, Bolt Threads
"With Benchling, it's so much faster and easier to find the information that you want, and share information even in real time. Series of experiments go faster, program timelines go faster, and it shortens the timelines for the development of our therapeutics."
Cherylene PlewaAssociate Vice President of Molecular Biology & CARs, AgenTus Therapeutics
“What Benchling has provided us is a single solution for multiple different problems, from sequence design and alignment to a centralized database. Our speed has doubled, communication has improved exponentially, and it's decreased scientist frustration.”
Brenda MinesingerPrincipal Scientist, Intellia Therapeutics
“Working with Benchling as a partner has been a blast. Everyone that we’ve interacted with – from contracting through implementation – we have, to some level, loved.”
Patrick JohnsonTest Automation Engineer, Bolt Threads
“Simplicity and transparency across software is integral to where we’re taking our bioinformatics systems. Benchling is our access point to that vision.”
Dennis UnderwoodVP Molecular & Information Systems, Agenus
“Benchling has really put the data at our fingertips, whereas before it was so spread out and difficult to follow.”
Scott HamiltonManufacturing Team Leader, Synlogic
“Benchling has helped a lot with our communication, because it's one site for all of our key information. It holds all of our sequence information, all of our data, and all of our experimental protocols.”
Tiffany ChenDirector of Discovery, Rubius Therapeutics
“Benchling gives us the ability to do long-term analysis of the data being produced by our research and development groups. It’s also been a really effective communication and collaboration tool for us.”
Jeanette GrantAssociate Director of Project Management, Adicet Bio
More than 215,000 scientists worldwide across pharma, biotech, and academia
One of the world's largest pharmaceutical companies developing cutting-edge drugs in immunology, oncology, cardiology, and more.
A leading biotechnology company using the power of science to bring new medicines to patients in need.
Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways, delivering medicines, vaccines, and diagnostic products.
Ginkgo Bioworks is designing custom organisms for customers across multiple markets, learning from nature to replace technology with biology.
Mammoth Biosciences provides a CRISPR-based platform for disease detection across healthcare, agriculture, and other industries
Daiichi Sankyo Inc
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan.
Eisai is a human health care (hhc) company seeking innovative solutions in disease prevention, treatment and care for the health and well-being of people worldwide.
Beam is pioneering the use of base editing — a potential new class of precision genetic medicines — with a vision of providing life-long cures to patients suffering from serious diseases.
BP’s Biosciences Center conducts innovative research, supports strategic investments and manages academic partnerships designed to accelerate the global transition to a low-carbon future.
ArsenalBio was founded to discover, develop and commercialize curative immune cell therapies.
Developing novel first-in-class therapeutics targeted at Natural Killer cells and other cells of the innate immune system.
Making xenotransplantation a routine medical procedure for the delivery of safe & effective human transplantable cells, tissues & organs.
IGM is pioneering the development of the IgM class of antibodies as therapeutic treatments for human disease.
Invaio Sciences is a transformative early-stage startup developing a platform to control the fitness and behavior of pests and target insects in a targeted, sustainable, and natural way.
Kymera Therapeutics is pioneering a new therapeutic modality and platform to transform drug discovery and deliver breakthrough medicines for previously untreatable diseases.
Tenaya is addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle.
TScan is harnessing novel T cell systems to extend the promise of immunotherapy.
Arcus is utilizing its small molecule discovery and development capabilities to create innovative cancer immunotherapies.
Bioverativ Inc. is an American multinational biotechnology that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia.
Surrozen is discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.
A premier human antibody discovery and optimization platform defined by speed, diversity, and quality.
Providing a stable and cost-competitive supply of plant-based medicines and to transform the discovery, manufacture, and distribution of medicines.
Atreca focuses on the immune responses of patients to discover and develop novel immunotherapies.
Cedilla is harnessing intrinsic protein stability mechanisms to broaden the reach of small molecule therapeutics to work on diseases caused by protein dysregulation.
Cue Biopharma is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system.
CytomX is a clinical-stage biopharmaceutical company – intent on revolutionizing the way we treat cancer.
Leveraging a platform focused on T cell engagement to discover and develop novel biologics for the treatment of cancer and other diseases
HiberCell is developing first-in-class therapeutics that target dormant disseminated tumor cells from solid and liquid cancers to the prevent or delay the recurrence of cancer.
Lung Biotechnology's mission is to simplify and democratize the treatment of lung disease, using biotechnology to design therapies for PAH and other fatal lung diseases.
Discovering transformative new treatments by leveraging the speed of automation with the intelligence of computers.
Leveraging expertise in cell engineering and biological programming to build the future of gene and cell based therapies.
Translate Bio is an mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
Delivering on the promise of gene therapy, single treatments with potentially curative results.
Expanding the therapeutic boundaries of monoclonal antibody drugs with its XmAb antibody engineering platform.
We have built a next-generation biodiscovery platform to uncover novel CRISPR enzymes and systems that can power transformative applications across a range of industries.
At Arch Oncology, we are aiming high to discover and develop new antibody therapeutics to treat patients living with cancer.
At Arvinas, we’re leading the creation of an entirely new way to treat disease through therapies that target and degrade disease-related proteins.
Cogen Therapeutics develops immune modulation therapeutics that control the immune system, targeting the specific drivers of disease.
Sound Agriculture, formerly known as Asilomar Bio, is developing technologies to help growers sustainably increase productivity by enhancing crop nutrient and water use.
Synbal, Inc. is using its proprietary next-generation gene-editing platform, Active Genetics, to develop safer, non-viral, cell-based gene therapy candidates.
Our mission is to eliminate neurodegeneration through immuno-neurology. This is a therapeutic approach that harnesses the body's own immune system to combat these devastating diseases.
ABL Bio is one of the world's leading biotech research companies focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases.
Carisma Therapeutics is pioneering CAR macrophage immunotherapy to target solid tumors.
Cygnal Therapeutics is developing drugs to manipulate exoneural biology for the treatment of cancer, immunological diseases, and regenerative processes.
Developing a new class of targeted biotherapeutic agents to selectively intervene on the microbiome.
Developing and delivering innovative therapies that harness the human gut microbiome.
Investigating the immune-suppressive tumor microenvironment through both small and large molecule approaches that target diverse mechanisms.
Redirected T cell therapeutics designed to deliver potent activity with increased tumor specificity and reduced toxicity.
Building cell therapies with pharmacologic operating systems to provide treating physicians with precise and dynamic control of engineered cells in patients.
Developing next-generation therapeutic antibodies to directly target cytosolic proteins associated with many human diseases that have been previously considered untreatable.
Shifting the paradigm from systemic immunosuppression to localized immunomodulation with the next generation of targeted therapeutics.
Developing life-changing gene therapies with a focus on severe neurological diseases that lack safe and effective treatment options.
Amunix is leveraging our expertise in precision protein engineering to enable the promise of T cell engagers in solid tumors.
CERo Therapeutics, Inc. is a new cellular immunotherapy company. We have created a hybrid platform that integrates innate and adaptive programs to eliminate disease.
We’re unlocking the complexities of the immune system to develop highly effective, precisely targeted therapies for cancer and autoimmune diseases.
We’re unlocking the complexities of the immune system to develop highly effective, precisely targeted therapies for cancer and autoimmune diseases
D2G Oncology relates drugs to genotypes to transform precision cancer therapeutics.
Dyno Therapeutics is leading a machine learning revolution to develop technologies that dramatically enhance new therapies for genetic disease.
We are pioneering the development of synthetic biomarkers that are bioengineered to be perfectly tunable to any disease, absolutely specific, and offer earlier measures of response.
We are an emerging biotechnology company that develops precision antibacterial products.
OncoMyx Therapeutics is developing oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer.
We are developing Anellovectors™, the first potentially redosable and targetable gene therapy platform, by harnessing the human commensal virome
We are developing next-generation immunotherapies with improved efficacy and safety.
Strand is increasing mRNA therapy safety and efficacy by programming the location, timing, and intensity of therapeutic protein expression inside a patient’s body using mRNA-encoded logic circuits.
enGene has developed a robust non-viral gene-therapy platform to transport DNA sequences across mucosal barriers.
Discovering small molecule drugs that target functional 3D RNA structures to treat human diseases.
Asimov strives to enable biotechnologies with global benefit by combining synthetic biology and computer science.
Developing and delivering innovative therapies that harness the human gut microbiome.
Making cancer screening and diagnostics as accurate and accessible as possible, through a fusion of machine learning, biology and computer science.
A leading gene editing company that designs and engineers genetically modified cells for clinical applications.
Enabling fit-for-function biotherapeutics that optimally interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling.
Jnana is pushing the frontiers of knowledge and technology to decipher the language of cellular metabolite communication and unlock SLC transporters as a therapeutic target class.
Harnessing the body's natural DNA repair process to provide precise, stable, and durable therapies to patients with serious genetic diseases.
Lumen Bioscience makes oral antibody therapeutics.
Harnessing the innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’' cells.
NeuCyte is an innovative biotechnology company focused on CNS drug discovery. NeuCyte has developed an in vitro platform for neurotoxicity assessment, disease modeling, and more.
Improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data driven design.
3T Biosciences is solving a major bottleneck in the field of immunotherapy – identifying novel targets that can be used to generate therapies to treat cancer in broad patient populations.
Aralez Bio uses engineered enzymes to make valuable products in a sustainable way.
Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine.
GO Therapeutics is developing a range of cancer drug candidates that are exquisitely tumor specific.
GPCR Therapeutics, Inc. is developing pharmaceuticals based on the cutting-edge knowledge of G Protein-Coupled Receptors (GPCRs).
We leverage the body’s robust signaling networks to pioneer PEM™ compounds, a new class of precision-based orally available small molecule therapeutics to restore health and fight disease.
Lygos employs cutting edge synthetic biology techniques to generate microbial catalysts to convert agricultural feedstocks into fine and commodity chemicals.
NovoNutrients transforms waste industrial CO2 into feed, through industrial biotech, initially for the fast-growing aquaculture sector.
RootPath is a Cambridge-based biotechnology company developing a powerful personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy.
TCRCure possesses streamlined biotechnology development including vector and cell manufacturing, which enables clinical translation intended for full-fledged immunotherapy services
We see a future where biotechnology improves the sustainability of food supply production, processing, and packaging.
Since its foundation, we have dedicated ourselves to the discovery & development of novel antibody therapeutics.
AgBiome develops innovative, cutting-edge solutions using new knowledge of the plant-associated microbiome to create novel products.
Engineering microorganisms to produce valuable bio-based products from renewable feedstocks.
EnginZyme engineers cost-competitive biocatalytic solutions fast than ever before, using their universal system for enzyme immobilization.
Investigating the application of novel gene editing technologies towards bovine genetics.
We are a science-driven biopharmaceutical start-up on a mission to deliver innovative antibody-based medicines for the treatment of immune disorders and inflammatory diseases.
The Future of the Microbiome - Harnessing the power of defined complex microbial communities to provide a robust and lasting cure for high unmet need diseases
Good Therapeutics is developing "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity.
Gordian is extending the reach of gene therapy to diseases of aging via a novel screening platform.
MacrophOx is pioneering sophisticated genetic, immunological and cell biological solutions to the major challenges that currently limit cell therapy for cancer.
NAVAN Technologies, Inc. is an enabling technology company commercializing a novel non-viral delivery platform to radically accelerate genetic engineering of human primary cells.
PetMedix is using the highest quality science to make the medicines our pets need and deserve, keeping them healthier, happier, and for longer.
Specifica creates antibody libraries in single chain Fv or Fab formats, in phage or yeast display platforms, and based on natural or synthetic sources.
Akrevia Therapeutics is focused on developing highly potent, tumor-targeted immuno-oncology therapeutics.
Aether Biomachines is repurposing enzymes to reinvent previously discovered compounds and create novel compounds.
GeneQuine Biotherapeutics GmbH develops novel therapies for osteoarthritis, a degenerative joint disease with high unmet medical need.
We are revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing tools to empower people to become knowledgeable about their health.
Mining massive amounts of genomic data from fungal genomes to identify novel drugs for diseases with unmet needs.
RareCyte is enabling next-generation analysis of rare cells with an open and end-to-end platform that supports clinical trials worldwide.
Antel Biosystems (CentralStar Cooperative)
AntelBio is a leader in the development and application of innovative diagnostic solutions for the animal industry.
Apic Bio is committed to finding cures for patients with genetic diseases and is currently developing best-in-class treatment options for rare, devastating neurological and liver diseases.
Axitan has established a robust platform to engineer and grow microalgae in a cost effective and sustainable manner.
Biosyntia is a biotech startup within synthetic biology and metabolic engineering.
We Are Advancing Fermentation-based Cellular Agriculture to Produce Natural Molecules with Greater Purity, Consistency and Efficiency
EdiGene is translating cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer, and into creative solutions to advance drug discovery.
GigaGen develops novel antibody therapies for patients with diseases that result from immune system dysregulation including cancer and immune deficiencies.
Hunterian Medicine is a gene editing company poised to unleash the full potential of CRISPR.
Our specialty is in producing natural molecules, derivatives, and new targets using a fast and scalable platform based on engineered microbes.
ImmunAI provides a platform that combines biology with machine-learning to unravel the immune system.
Persona Biome is dedicated to finding the health we have lost — starting with your skin.
Admirx is a preclinical-stage company developing anti-complement therapies to treat life threatening auto-immune and inflammatory diseases.
Samplix is a biotechnology company that has developed a proprietary technology for single molecule sample preparation.
Scenic is pioneering genetic modifies for drug discovery to build a pipeline of breakthrough products.
We are a team of synthetic biologists and next-generation sequencing experts focused on disrupting the way that pharmaceutical companies discover, optimize, and characterize drugs.
Alkahest is targeting neurodegenerative and age-related diseases with transformative therapies derived from a deep understanding of the plasma proteome in aging and disease.
Amyloid Solution seeks to overcome Alzheimer's Disease by developing innovative disease-modifying treatments that address different stages of patients during the course of disease progression.
Aromyx uses the biological receptors from the human nose to create quantitative representations of sensory data for multiple applications.
Azitra Inc. is leveraging extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.
Creatus is developing one of the most attractive mixed-sugar biorefinery platforms in the industry
DefiniGEN are a Cambridge UK company providing highly functional disease model human cells including hepatocytes, pancreatic beta cells and intestinal organoids.
Diadem Biotherapeutics is pioneering the development of first-in-class engineered exosomes to treat chronic inflammatory and auto-immune conditions.
Empyrean Therapeutics is focused on developing next generation cell therapies to enable global and affordable cures for disease.
We are a team of highly experienced scientists specialised in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system.
GABAeron focuses on engineered stem cell lines, genetic data and small-molecule drugs in hopes of developing therapeutics to preserve and maybe restore brain function in Alzheimer’s.
We upgrade methan to chemicals using synthetic biology.
Leveragen is a Boston-based biotech startup company providing customized genetic modeling services.
With synthetic biology and fully automated bio-manufacturing, we enable industrialized, on-demand, high-throughput, and flexible engineering of biological systems for practical applications.
Membio is on a mission to ensure the world has a safe and sufficient supply of blood.
NemaMetrix Inc. is a biotechnology company that develops solutions and commercializes proprietary systems for the genetic modification of simple microscopic living animals.
Nucleo Life Sciences
Based in the San Francisco Bay Area, Nucleo Life Sciences is a boutique CMO that’s passionate about helping you take your drugs into the clinic—and the market—as quickly and effectively as humanly possible.
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer.
Our mission is to be the company you can trust to keep you young while you age.
We’re leveraging computer vision and high-content screening to develop the next wave of therapeutic antibodies against cancer and fibrosis.
With a proven track record in biopharmaceuticals, we aim to revolutionize advanced gene therapy to address unmet patient needs.
Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.
We are harnessing evolution in our synthetic biology based selection platforms to create and identify molecules that disrupt or bridge previously 'undruggable' protein-protein interactions.
At T2 Biosystems, our mission is to save lives and improve healthcare by empowering clinicians to get patients on the right therapy faster.
We are developing a new generation of biotechnology drugs that act precisely within a targeted diseased tissue.
Vectron Biosolutions AS
Vectron Biosolutions AS is your expert on developing cost-effective microbial production processes for recombinant proteins.
We are interested in changing the status quo by systematizing BIOLOGIC units and constructing modular composition rules.
Abalone is shifting the paradigm for antibody development, isolating drug candidates directly by their modulating effects on integral membrane proteins.
Anwita Biosciences is a San Francisco Bay Area startup company specializing in antibodies and fusion proteins for therapies in oncology and auto-immune disease.
We focus on complex genome engineering providing proprietary, cutting edge gene delivery and editing tools to enable faster research and cost effective therapies.
Biomeme's platform transforms your smartphone into a mobile lab for advanced DNA diagnostics and real-time disease surveillance.
BioPlx is an advanced microbiomics company developing non-antibiotic methods for the control of infectious disease, including multiple-drug resistant "super-bugs".
Quintara Biosciences specializes in providing high quality DNA sequencing and genomic services for life science research communities around the globe.
Seer is extracting deep molecular insights from the proteome to enable early detection of cancer and neurological diseases, drive earlier treatment, and improve patient outcomes.
Our mission is to develop microbes & bioprocesses that enable profitable and eco-friendly production of chemicals from renewable sources such as sugars.
Join over 215,000 scientists using
Benchling to power life science R&D